ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX

<table>
<tr><td>OTHER NAMES</td><td>Antihemophilic Factor/ Von Willebrand Factor Complex (Human),
von Willebrand Factor/Coagulation Factor VIII Complex (Human),
Humate P®, Wilate®</td></tr>
<tr><td>PRODUCT COMPOSITION</td><td>Purified, sterile, lyophilized concentrate of antihemophilic factor from human source. Has von Willebrand (vWf) and ristocetin cofactor and Factor VIII activity.</td></tr>
<tr><td>INFORMED CONSENT</td><td>Mandatory</td></tr>
<tr><td rowspan="2">ALTERNATIVES</td><td>Non-blood Product: Desmopressin (DDAVP)</td></tr>
<tr><td>Blood Product: Cryoprecipitated AHF provides a source of Factor VIII, fibrinogen and von Willebrand factor</td></tr>
<tr><td>DOSAGE</td><td>
<table>
<tr><th></th><th>Humate P®</th><th>Wilate®</th></tr>
<tr><td>VWF:RCo to FVIII activity</td><td>2.4:1</td><td>1:1</td></tr>
</table>

Dosage will depend on the extent and location of bleeding and the classification of Von Willebrand disease (VWD)
The manufacturer product monograph will provide specific dosage guidelines
Order as IU vWF (international units) and a timed frequency (e.g. Q12h)
Transfusion Medicine (TM) will provide the dose requested ±10% depending on available vial sizes (Wilate® is provided in 500IU and 1000IU strengths)

</td></tr>
<tr><td>ADMINISTRATION</td><td>

Reconstituted and filtered by TM and supplied to unit in a syringe
Product is best given immediately after preparation, MUST be within 3 hours of reconstitution
Should be inspected visually for particulate matter and discoloration prior to administration, Wilate® may be clear or slightly opalescent, colourless or slightly yellow
Should be given by slow IV injection, no more than 4mL per minute

Administer the entire amount
</td></tr>
<tr><td>DIAGNOSTIC MONITORING</td><td>Vital sign monitoring as per hospital policy for any blood, blood component and other related product. In the event of an immediate or suspected transfusion reaction, refer to hospital policy and procedures.

Usually tolerated without reaction
Rare cases of allergic reaction and rise in temperature have been observed

</td></tr>
<tr><td>CLINICAL INDICATIONS</td><td>
<table>
<tr><th>Humate P®</th><th>Wilate®</th></tr>
<tr><td rowspan="2">

In adult patients for treatment and prevention of bleeding in hemophilia A
In adult and pediatric patients

treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease
mild and moderate VWD where the response to DDAVP is unknown or suspected to be inadequate

</td><td>

For the treatment of spontaneous and trauma-induced bleeding episodes in patients with

severe VWD
mild or moderate VWD in whom the use of DDAVP is known or suspected to be ineffective or contraindicated

</td></tr>
<tr><td>Clinical trials to evaluate prophylactic dosing have not been conducted in VWD subjects</td></tr>
</table>
</td></tr>
</table>

	• To prevent excessive bleeding (i.e. bleeding that exceeds the expected blood loss under a given condition) during and after surgery	• **Not indicated** for the prevention of excessive bleeding during and after surgery in VWD patients • **Not indicated** for Hemophilia A
SPECIAL CONSIDERATIONS	• TM will need approximately 30 minutes preparation time • **Humate P®:** Preparation noted to contain blood group isoagglutinins (anti-A and anti-B). When very large or frequent repeated doses are needed (i.e. inhibitors present or pre/post-surgical care is involved, patients of blood group A, B, and AB should be monitored for signs of intravascular hemolysis and decreasing hematocrit values • When ordering product for a patient with VWD, order should reflect vWF units • TM needs prompt notification of changes of both dosage and/or frequency	
STORAGE CONDITIONS	DO NOT REFRIGERATE AFTER RECONSTITUTION	
REFERENCES	**Review product monograph**	
REFERENCES	**Review product monograph** • Provincial Blood Coordinating Office, *IVIG Utilization Management Handbook, 2002*	